KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

NovoCure (NVCR) EBIAT (2016 - 2025)

NovoCure's EBIAT history spans 12 years, with the latest figure at -$24.5 million for Q4 2025.

  • For Q4 2025, EBIAT rose 62.84% year-over-year to -$24.5 million; the TTM value through Dec 2025 reached -$136.2 million, up 19.21%, while the annual FY2025 figure was -$136.2 million, 19.21% up from the prior year.
  • EBIAT for Q4 2025 was -$24.5 million at NovoCure, up from -$37.3 million in the prior quarter.
  • Across five years, EBIAT topped out at -$4.1 million in Q1 2021 and bottomed at -$65.9 million in Q4 2024.
  • The 5-year median for EBIAT is -$33.8 million (2024), against an average of -$33.1 million.
  • The largest annual shift saw EBIAT crashed 1041.83% in 2023 before it skyrocketed 62.84% in 2025.
  • A 5-year view of EBIAT shows it stood at -$26.5 million in 2021, then tumbled by 40.99% to -$37.3 million in 2022, then decreased by 26.21% to -$47.1 million in 2023, then plummeted by 40.02% to -$65.9 million in 2024, then surged by 62.84% to -$24.5 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's EBIAT are -$24.5 million (Q4 2025), -$37.3 million (Q3 2025), and -$40.1 million (Q2 2025).